3 protocols found

Protocol No. Title Status
ALTE03N1 Key Adverse Events after Childhood Cancer Open
UW17054 Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology Open
UW18120 My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetnib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response with One of these Agents Open